AR114216A1 - Composiciones oftálmicas de compuestos de bencimidazol para uso único diario - Google Patents
Composiciones oftálmicas de compuestos de bencimidazol para uso único diarioInfo
- Publication number
- AR114216A1 AR114216A1 ARP190100094A ARP190100094A AR114216A1 AR 114216 A1 AR114216 A1 AR 114216A1 AR P190100094 A ARP190100094 A AR P190100094A AR P190100094 A ARP190100094 A AR P190100094A AR 114216 A1 AR114216 A1 AR 114216A1
- Authority
- AR
- Argentina
- Prior art keywords
- daily use
- single daily
- ophthalmic compositions
- benzimidazole compounds
- bilastine
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Ophthalmology & Optometry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente se refiere a una composición farmacéutica oftálmica acuosa que comprende: a) al menos el 0,4% p/v de bilastina, o una sal o solvato farmacéuticamente aceptable de la misma, en la que la bilastina, de fórmula (1) o una sal o solvato de la misma se disuelve completamente en la composición farmacéutica; b) al menos una b-ciclodextrina; y c) al menos un agente de gelificación soluble en agua farmacéuticamente aceptable; y en la que el pH está comprendido entre 4 y 9, y a su uso en el tratamiento y/o la prevención de estados mediados por receptor de histamina H1, tales como trastornos o enfermedades alérgicos. La presente se refiere al tratamiento y/o prevención de conjuntivitis alérgica.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18382021 | 2018-01-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR114216A1 true AR114216A1 (es) | 2020-08-05 |
Family
ID=61017875
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP190100094A AR114216A1 (es) | 2018-01-18 | 2019-01-17 | Composiciones oftálmicas de compuestos de bencimidazol para uso único diario |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US20210128544A1 (es) |
| EP (2) | EP3740191B1 (es) |
| JP (1) | JP7309729B2 (es) |
| KR (1) | KR102695627B1 (es) |
| CN (1) | CN111727035B (es) |
| AR (1) | AR114216A1 (es) |
| AU (1) | AU2019209214B2 (es) |
| BR (1) | BR112020014265A2 (es) |
| CA (1) | CA3088740A1 (es) |
| CL (1) | CL2020001895A1 (es) |
| CO (1) | CO2020009992A2 (es) |
| CY (1) | CY1124270T1 (es) |
| DK (1) | DK3740191T3 (es) |
| EA (1) | EA202091725A1 (es) |
| ES (1) | ES2878107T3 (es) |
| HR (1) | HRP20211037T1 (es) |
| HU (1) | HUE054594T2 (es) |
| LT (1) | LT3740191T (es) |
| MA (1) | MA51612B1 (es) |
| MX (1) | MX2020007692A (es) |
| PL (1) | PL3740191T3 (es) |
| PT (1) | PT3740191T (es) |
| SA (1) | SA520412443B1 (es) |
| SI (1) | SI3740191T1 (es) |
| TW (1) | TWI833727B (es) |
| UY (1) | UY38055A (es) |
| WO (1) | WO2019141563A1 (es) |
| ZA (1) | ZA202005077B (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20250228836A1 (en) | 2022-02-17 | 2025-07-17 | Faes Farma, S.A. | Bilastine composition for once-daily parenteral administration |
| CN116211795B (zh) * | 2022-12-26 | 2025-09-26 | 深圳市贝美药业有限公司 | 一种比拉斯汀口服液体制剂及其制备方法 |
| CN115970066B (zh) * | 2022-12-29 | 2024-09-27 | 成都爱睿康乐医疗器械有限公司 | 基于主客体相互作用的载药纳米凝胶生物润滑剂及其制备方法和应用 |
| WO2024224308A1 (en) * | 2023-04-27 | 2024-10-31 | Leiutis Pharmaceuticals Llp | Liquid parenteral formulations of bilastine free of cyclodextrins |
| WO2024224326A1 (en) * | 2023-04-27 | 2024-10-31 | Leiutis Pharmaceuticals Llp | Liquid parenteral formulations of bilastine |
| WO2024256956A1 (en) * | 2023-06-13 | 2024-12-19 | Leiutis Pharmaceuticals Llp | Stable formulations of bilastine for nasal and ophthalmic use |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1229075B (it) * | 1985-04-05 | 1991-07-17 | Fidia Farmaceutici | Medicamenti per uso topico, ottenuti tramite l'impiego dell'acido ialuronico |
| ES2048109B1 (es) | 1992-07-20 | 1994-12-16 | Espanola Prod Quimicos | Procedimiento de preparacion de nuevos derivados piperidicos del bencimidazol. |
| JP3527256B2 (ja) | 1992-12-09 | 2004-05-17 | ロート製薬株式会社 | 抗アレルギー点眼剤 |
| TW401300B (en) * | 1992-12-25 | 2000-08-11 | Senju Pharma Co | Antiallergic composition for ophthalmic or nasal use |
| ES2124167B1 (es) | 1996-06-04 | 1999-09-16 | Espanola Prod Quimicos | Nuevos derivados del bencimidazol con actividad antihistaminica. |
| DE10161149B4 (de) * | 2001-12-12 | 2007-03-08 | Ursapharm Arzneimittel Gmbh & Co. Kg | Verwendung von Heparin-haltigem Ophthalmikum |
| CN1290843C (zh) | 2002-04-19 | 2006-12-20 | 费斯制药股份有限公司 | 4－[2－[4－[1－(2－乙氧基乙基)－1H－苯并咪唑－2－基]－1－哌啶基]乙基]－α,α－二甲基苯乙酸的多晶型物 |
| US20050239745A1 (en) | 2004-03-03 | 2005-10-27 | Ophthalmic Research Associates, Inc. | Novel topical ophthalmic formulations |
| US7247623B2 (en) | 2005-08-19 | 2007-07-24 | Inspire Pharmaceuticals, Inc. | Method of treating dry eye disease with non-drying antihistamines |
| US20070082870A1 (en) | 2005-10-11 | 2007-04-12 | Buchanan Charles M | Pharmaceutical formulations of cyclodextrins and antifungal azole compounds |
| WO2007117971A2 (en) | 2006-03-31 | 2007-10-18 | Vistakon Pharmaceuticals, Llc | Ocular allergy treatments |
| CN101460176B (zh) * | 2006-03-31 | 2012-11-28 | 维斯塔肯药品有限责任公司 | 眼变态反应治疗 |
| EP2173169B1 (en) | 2007-06-28 | 2014-05-21 | CyDex Pharmaceuticals, Inc. | Nasal delivery of aqueous corticosteroid solutions |
| US20100240624A1 (en) * | 2009-03-17 | 2010-09-23 | Aciex Therapeutics, Inc. | Ophthalmic Formulations of Ketotifen and Methods of Use |
| TWI544922B (zh) | 2011-05-19 | 2016-08-11 | 愛爾康研究有限公司 | 高濃度歐羅派特錠（ｏｌｏｐａｔａｄｉｎｅ）眼用組成物 |
| CN103110575B (zh) * | 2013-03-07 | 2014-11-05 | 宁夏康亚药业有限公司 | 一种美洛昔康滴眼液及其制备方法和应用 |
| WO2014150899A1 (en) * | 2013-03-15 | 2014-09-25 | Chapin Matthew J | Topical ophthalmic formulations for treating migraine |
| CN103784462A (zh) | 2014-02-25 | 2014-05-14 | 宋俊智 | 包含比拉斯汀及甾族化合物的药物制剂 |
| EP3040334A1 (en) | 2014-12-29 | 2016-07-06 | Faes Farma, S.A. | New benzimidazole derivatives as antihistamine agents |
-
2019
- 2019-01-09 EP EP19701154.7A patent/EP3740191B1/en active Active
- 2019-01-09 ES ES19701154T patent/ES2878107T3/es active Active
- 2019-01-09 JP JP2020539288A patent/JP7309729B2/ja active Active
- 2019-01-09 LT LTEP19701154.7T patent/LT3740191T/lt unknown
- 2019-01-09 AU AU2019209214A patent/AU2019209214B2/en active Active
- 2019-01-09 KR KR1020207023573A patent/KR102695627B1/ko active Active
- 2019-01-09 BR BR112020014265-4A patent/BR112020014265A2/pt active IP Right Grant
- 2019-01-09 EP EP21169956.6A patent/EP3915539A1/en not_active Withdrawn
- 2019-01-09 PT PT197011547T patent/PT3740191T/pt unknown
- 2019-01-09 EA EA202091725A patent/EA202091725A1/ru unknown
- 2019-01-09 CN CN201980009293.0A patent/CN111727035B/zh active Active
- 2019-01-09 PL PL19701154T patent/PL3740191T3/pl unknown
- 2019-01-09 CA CA3088740A patent/CA3088740A1/en not_active Abandoned
- 2019-01-09 US US16/963,219 patent/US20210128544A1/en not_active Abandoned
- 2019-01-09 WO PCT/EP2019/050433 patent/WO2019141563A1/en not_active Ceased
- 2019-01-09 HR HRP20211037TT patent/HRP20211037T1/hr unknown
- 2019-01-09 HU HUE19701154A patent/HUE054594T2/hu unknown
- 2019-01-09 MA MA51612A patent/MA51612B1/fr unknown
- 2019-01-09 MX MX2020007692A patent/MX2020007692A/es unknown
- 2019-01-09 SI SI201930076T patent/SI3740191T1/sl unknown
- 2019-01-09 DK DK19701154.7T patent/DK3740191T3/da active
- 2019-01-17 AR ARP190100094A patent/AR114216A1/es not_active Application Discontinuation
- 2019-01-17 TW TW108101861A patent/TWI833727B/zh active
- 2019-01-18 UY UY38055A patent/UY38055A/es not_active Application Discontinuation
-
2020
- 2020-07-15 SA SA520412443A patent/SA520412443B1/ar unknown
- 2020-07-17 CL CL2020001895A patent/CL2020001895A1/es unknown
- 2020-08-13 CO CONC2020/0009992A patent/CO2020009992A2/es unknown
- 2020-08-17 ZA ZA2020/05077A patent/ZA202005077B/en unknown
-
2021
- 2021-06-25 CY CY20211100569T patent/CY1124270T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR114216A1 (es) | Composiciones oftálmicas de compuestos de bencimidazol para uso único diario | |
| PE20191650A1 (es) | Derivados de indolina sustituidos como inhibidores de la replicacion virica de dengue | |
| MA40111A1 (fr) | Dérivés du tétrahydronaphtalène inhibant la protéine mcl-1 | |
| BR112015029491A2 (pt) | derivados de imidazopirrolidinona e seu uso no tratamento de doença | |
| AR108046A1 (es) | Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue | |
| NO20090723L (no) | Kondenserte heterosykliske derivater og fremgangsmater for anvendelse | |
| BR112015029512A2 (pt) | derivados de pirazolopirrolidina e seu uso no tratamento de doenças | |
| AR088195A1 (es) | Composiciones farmaceuticas de n-metil-2-[3-(e)-2-piridin-2-il-vinil)-1h-indazol-6-ilsulfanil]-benzamida | |
| BR112012012529A2 (pt) | composto indol e seu uso farmacêutico | |
| EP4306523A3 (en) | Imidazoquinoline compounds and uses thereof | |
| DOP2018000115A (es) | Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso en el tratamiento del cáncer | |
| BRPI0921097B8 (pt) | composto ou seu sal farmaceuticamente aceitável, intermediário do composto, composição farmacêutica e uso do composto | |
| EP2796450A4 (en) | 6-AMINOPYRIDIN-3-OL DERIVATIVES OR PHARMACEUTICAL SALTS AND / OR PHARMACEUTICAL COMPOSITION THEREOF AS ACTIVE AGENTS FOR THE PREVENTION OR TREATMENT OF ANGIOGENESIS-MEDIATED DISEASES | |
| NI201900094A (es) | COMPUESTOS DE TIPO IMIDAZO[4, 5-c]QUINOLIN-2-ONA DEUTERADOS Y SU USO EN EL TRATAMIENTO DEL CÁNCER | |
| CU20130168A7 (es) | Composición farmacéutica oftalmológica tópica que contiene regorafenib | |
| CO2017005806A2 (es) | Nuevos derivados de bencimidazol como agentes antihistamínicos | |
| AR127431A1 (es) | Compuestos novedosos | |
| WO2018234871A3 (en) | COMPOSITIONS FOR DRUG DELIVERY AND METHODS OF USE | |
| MA33563B1 (fr) | 5-(3,4-dichloro-phényl)-n-(2-hydroxy-cyclohexyl)-6-(2,2,2-trifluoro-éthoxy)-nicotinamide et ses sels utilisés comme agents augmentant le cholestérol hdl | |
| BR112017021583A2 (pt) | métodos para o tratamento de transtornos inflamatórios | |
| CO2020005939A2 (es) | Composiciones acuosas que comprenden bilastina y mometasona | |
| CL2020001426A1 (es) | Composición tópica oftálmica que comprende ácido dobesilico para tratar enfermedades del segmento posterior del ojo. | |
| MX2017009853A (es) | Prevencion o tratamiento de enfermedades urinarias o gotosas. | |
| MX2020004477A (es) | Formulaciones de liberacion prolongada para aplicaciones intra-articulares. | |
| SA521421098B1 (ar) | -h4 مركبات بيريدو بيريميدينات كمثبطات مستقبل هستامين |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |